A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
Public ClinicalTrials.gov record NCT00880399. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT00880399
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 328 participants
Conditions and interventions
Conditions
Interventions
- orvepitant Drug
- placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- May 31, 2010
- Completion
- Jun 15, 2010
- Last update posted
- Sep 11, 2017
2009 – 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35216 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Arcadia | California | 91007 | — |
| GSK Investigational Site | Beverly Hills | California | 90210 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Bradenton | Florida | 34208 | — |
| GSK Investigational Site | Maitland | Florida | 32751 | — |
| GSK Investigational Site | North Miami | Florida | 33161 | — |
| GSK Investigational Site | Orlando | Florida | 32806 | — |
| GSK Investigational Site | Overland Park | Kansas | 66212 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Toledo | Ohio | 43623 | — |
| GSK Investigational Site | Lincoln | Rhode Island | 02868 | — |
| GSK Investigational Site | Seattle | Washington | 98104 | — |
| GSK Investigational Site | Middleton | Wisconsin | 53562 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00880399, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00880399 live on ClinicalTrials.gov.